Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McMaster University

$135,000.00

Development of bioengineered exosomes for next-generation STING immunotherapies

FY 2021-22

Summary
The environment that surrounds a tumor contains many different types of cells, including infiltrating immune cells, such as dendritic cells (DCs) and macrophages. These two immune cell types play a vital role in influencing the growth or death of nearby cancerous cells. Notably, there is a unique intracellular immune defence system called STING, which can activate DCs and macrophages when turned on. These activated immune cells are then able to mount a very potent immune response by producing pro-inflammatory molecules and recruiting other immune cells. Interestingly, this defence system evolved to bind to molecules commonly produced by bacterial enzymes in order to fight off infection. Therefore, we screened dozens of these enzymes to find ones that function optimally in human cells. The goal was to produce this bacterial enzyme in human cells and specifically deliver it to DCs and macrophages. Upon successful delivery of this bacterial enzyme, it will produce the molecules needed to turn on the STING immune defence system in the recipient immune cells and enable them to mount a potent immune response directed at the cancer. To deliver this functional enzyme, we are exploiting the cells' natural mail delivery system called exosomes, and biologically engineering them with a "postal code" to specifically deliver our therapeutic package to DCs and macrophages. These exosomes can be "custom-designed" to target any cell of interest and deliver different therapeutic payloads. We have successfully designed and bioengineered these exosomes to target DCs and macrophages and deliver a functional STING-activating enzyme. We have also shown that we can boost immune responses directed at foreign proteins of our choosing, when targeting our bioengineered therapy to DCs, which has implications for the immunotherapy of cancer. These initial studies will help us identify lead candidates to manufacture and clinically test, in order to develop next-generation cancer immunotherapies.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
454959
Name
Gameiro Steven F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of bioengineered exosomes for next-generation STING immunotherapies
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Animal Models; Bioengineering; Cancer Immunotherapy; Dendritic Cells; Extracellular Vesicles; Immunology; Macrophages; Oncolytic Virus; Sting; Tumor Microenvironment
Abstract
The environment that surrounds a tumor contains many different types of cells, including infiltrating immune cells, such as dendritic cells (DCs) and macrophages. These two immune cell types play a vital role in influencing the growth or death of nearby cancerous cells. Notably, there is a unique intracellular immune defence system called STING, which can activate DCs and macrophages when turned on. These activated immune cells are then able to mount a very potent immune response by producing pro-inflammatory molecules and recruiting other immune cells. Interestingly, this defence system evolved to bind to molecules commonly produced by bacterial enzymes in order to fight off infection. Therefore, we screened dozens of these enzymes to find ones that function optimally in human cells. The goal was to produce this bacterial enzyme in human cells and specifically deliver it to DCs and macrophages. Upon successful delivery of this bacterial enzyme, it will produce the molecules needed to turn on the STING immune defence system in the recipient immune cells and enable them to mount a potent immune response directed at the cancer. To deliver this functional enzyme, we are exploiting the cells' natural mail delivery system called exosomes, and biologically engineering them with a "postal code" to specifically deliver our therapeutic package to DCs and macrophages. These exosomes can be "custom-designed" to target any cell of interest and deliver different therapeutic payloads. We have successfully designed and bioengineered these exosomes to target DCs and macrophages and deliver a functional STING-activating enzyme. We have also shown that we can boost immune responses directed at foreign proteins of our choosing, when targeting our bioengineered therapy to DCs, which has implications for the immunotherapy of cancer. These initial studies will help us identify lead candidates to manufacture and clinically test, in order to develop next-generation cancer immunotherapies.
Competitiondate
202110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gameiro, Steven F
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~